Dover Advisors LLC Cuts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Dover Advisors LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 26.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,340 shares of the medical research company’s stock after selling 852 shares during the quarter. Thermo Fisher Scientific comprises about 1.6% of Dover Advisors LLC’s holdings, making the stock its 17th biggest holding. Dover Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,243,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TMO. Monumental Financial Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 4.6% during the 4th quarter. Monumental Financial Group Inc. now owns 2,196 shares of the medical research company’s stock valued at $1,166,000 after acquiring an additional 96 shares during the last quarter. Silver Oak Securities Incorporated bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $240,000. Magnus Financial Group LLC lifted its stake in shares of Thermo Fisher Scientific by 2.9% in the 4th quarter. Magnus Financial Group LLC now owns 3,076 shares of the medical research company’s stock worth $1,633,000 after purchasing an additional 88 shares during the period. Little House Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 2.8% in the 4th quarter. Little House Capital LLC now owns 4,590 shares of the medical research company’s stock worth $2,436,000 after purchasing an additional 127 shares during the period. Finally, Legacy Capital Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 13.1% in the 4th quarter. Legacy Capital Wealth Partners LLC now owns 1,885 shares of the medical research company’s stock worth $1,001,000 after purchasing an additional 218 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last quarter. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of TMO stock traded up $1.87 during trading hours on Friday, reaching $573.60. 1,438,184 shares of the company’s stock were exchanged, compared to its average volume of 1,317,052. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market cap of $218.95 billion, a PE ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The stock’s fifty day moving average price is $573.60 and its two-hundred day moving average price is $530.40.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. The Goldman Sachs Group raised their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Barclays raised their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.